Clinical Trials Directory
This study begins with a screening period that lasts about 28 days to see if a person can join. If eligible, participants will receive a study medicine called JANX014. This is a new immune based drug that is given through a vein at a clinic or hospital. The medicine may be given once every week, every two weeks, or every three weeks, depending on the study group and safety results. The study has two parts. In the first part, small groups receive different dose levels to find a safe amount of the medicine. In the second part, more people receive selected doses to learn more about safety and early effects. During the study, participants will have regular visits that include physical exams, blood and urine tests, heart tests, and imaging scans such as CT or PET scans. Some early treatment visits may require short hospital stays so doctors can watch closely. Participants may also check their temperature and blood pressure at home.
You will be in this study for about 122 weeks. The study has three parts called Screening, Treatment, and Follow up. During screening, which can last up to six weeks, doctors will do tests to see if you can join. If you qualify, you will be placed by chance into one of two groups. One group will get a study drug called anifrolumab, and the other will get a placebo, which looks like the medicine but has no active drug. You will also keep taking your regular medicines for polymyositis or dermatomyositis. You must stay on the same dose of your regular medicines for at least the first eight weeks of the study.
Copilot said: Participation in this study requires very little time. The research muscle biopsy will be done at the same time as the biopsy that is already planned as part of regular medical care. After that, no additional study visits or time commitments are needed.
We are doing this study to find out if an experimental drug called KTX-1001 (the study drug) is a safe and effective treatment for multiple myeloma. We want to identify the most appropriate dose and dosing schedule of the study drug for patients with multiple myeloma.
We are doing this study to compare a ketogenic diet (a diet with high fat, moderate protein, very low carbohydrate) versus a normal diet. We want to find out if it has any effect on survival time for people with glioblastoma multiforme (GBM). We also want to know how biomarkers change when people follow a ketogenic diet. A biomarker is a biological molecule found in blood, other body fluids, or tissues. Biomarkers may be a sign of a condition or disease and can be used to predict someone's response to a specific treatment.
We are doing this study to learn more about what causes glioblastoma (GBM), a type of brain cancer, and the factors that affect GBM patients' quality of life. This research will help us to understand why some people get GBM, including how their genes and health history may contribute to tumor development and progression.
This study has two parts. The first part includes about eighty people, and the second part includes about two hundred fifty people. Each part of the study lasts about thirty six weeks. The study begins with screening to see if someone can join. After that, people are placed by chance into groups to take either the study medicine or a placebo for about twenty-eight weeks. At the end, there is a follow up period where doctors check safety. Each person will join only one part of the study.